KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Assets (2016 - 2025)

Historic Assets for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $3.5 billion.

  • Sarepta Therapeutics' Assets fell 295.83% to $3.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 billion, marking a year-over-year decrease of 295.83%. This contributed to the annual value of $4.0 billion for FY2024, which is 2139.93% up from last year.
  • As of Q3 2025, Sarepta Therapeutics' Assets stood at $3.5 billion, which was down 295.83% from $3.7 billion recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Assets ranged from a high of $4.0 billion in Q4 2024 and a low of $2.7 billion during Q3 2021
  • For the 5-year period, Sarepta Therapeutics' Assets averaged around $3.2 billion, with its median value being $3.1 billion (2021).
  • Per our database at Business Quant, Sarepta Therapeutics' Assets crashed by 618.02% in 2021 and then soared by 2139.93% in 2024.
  • Over the past 5 years, Sarepta Therapeutics' Assets (Quarter) stood at $3.1 billion in 2021, then fell by 0.62% to $3.1 billion in 2022, then increased by 4.35% to $3.3 billion in 2023, then grew by 21.4% to $4.0 billion in 2024, then decreased by 11.85% to $3.5 billion in 2025.
  • Its Assets was $3.5 billion in Q3 2025, compared to $3.7 billion in Q2 2025 and $3.5 billion in Q1 2025.